BioSpace News Archive

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2023.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, announced its cash position as of December 31, 2023 and revenues for 2023.

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted select corporate achievements.

Metagenomi, Inc. (Nasdaq: MGX) today announced that Brian C. Thomas, CEO & Founder, will participate in a panel titled, “Emerging Genetic Therapy Approaches,” during the 44th Annual Cowen Healthcare Conference on Wednesday, March 6, 2024 from 12:50-1:50 PM ET in Boston.

SQZ Biotechnologies Company announced the results for the proposals considered and voted upon by its shareholders at its special meeting on February 29, 2024.

Today at leading laboratory science conference Pittcon, Confience revealed its product roadmap and executive team expansion as part of the newly formed company’s North American launch.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 44th Annual Health Care Conference.

Synaptive Medical Inc., a global med tech and technology company solving surgical, imaging and data challenges, is proud to announce the appointment of Chris Marrus as Chief Commercial Officer.

Cosmos Health Inc. announced the successful acquisition of the distribution network owned by Pharmatrade S.A., an established pharmaceutical wholesale company operating in Greece.

Cue Biopharma, Inc. announced today that the company’s lead clinical asset, CUE-101, will be featured in a presentation at the 2024 Multi-disciplinary Head and Neck Cancers Symposium given by Alexander Dimitrios Colevas, M.D., a principal investigator at Stanford University participating in the CUE-101 clinical trial.